Highest-materiality recent filing
Fate Therapeutics Q1 2026: $174.8M cash, $1.3M revenue; FT819 lupus trial on track
Cash, equivalents, and investments of $174.8M as of March 31, 2026; operating runway extended into 2028.
Fate Therapeutics Q4: cash $205M, OpEx down 30%, FT819 outpatient treatment milestone
Cash and investments $205.1M as of Dec 31, 2025; operating runway through year-end 2027.
Fate Therapeutics Q3 cash $225.7M; UK/EU approval for FT819; first SSc patient treated
Cash, cash equivalents & investments $225.7M; projected runway through year-end 2027.
FT819 SLE data: 10 patients show durable responses; expansion cohorts; pivotal study planned 2026
10 SLE patients treated; 2 with lupus nephritis achieved CRR at 6 months; 1 in DORIS at 15 months.
Fate Therapeutics Q2 2025 cash $248.9M; 12% workforce cut; FT819 lupus response durable
Q2 2025 cash, cash equivalents & investments $248.9M; total revenue $1.9M from Ono collaboration; operating expenses $38.9M.
Fate Therapeutics appoints Matthew Abernethy to board; shareholders boost authorized shares to 350M
Matthew Abernethy, CFO of Neurocrine Biosciences, appointed Class III director; Timothy P. Coughlin steps down.
Fate Therapeutics Q1 cash $272.7M; FT819 gets RMAT designation for SLE
Cash, equivalents, and investments $272.7M as of March 31, 2025; projected runway through 1H27.
Fate Therapeutics: $306.7M cash runway through YE26; FT819 Phase 1 dose expansion in SLE underway
Cash, cash equivalents and investments of $306.7M; projected operating runway through year-end 2026.
J. Scott Wolchko retired as President, CEO, and CFO effective Dec 31, 2024; resignation not due to any policy disagreement.
Fate Therapeutics CEO Scott Wolchko to retire Dec 31; succeeded by Bob Valamehr
Wolchko resigned from board Nov 27, 2024; will retire as President & CEO effective Dec 31, 2024.
Fate Therapeutics Q3 rev $3.1M, cash $330.5M; FT819/FT522/FT825 clinical progress
Q3 revenue of $3.1M from Ono collaboration; total op expense $55.5M incl $11.8M stock comp.
Cash, equivalents & investments $352.0M; projected operating runway through YE26.
CEO J. Scott Wolchko assumes CFO role after Edward Dulac's resignation; stock plan expanded
CFO Edward Dulac resigned effective June 14, 2024; CEO J. Scott Wolchko appointed as CFO and principal financial/accounting officer.
Fate Therapeutics Q1 revenue $1.9M; $391M cash; advances FT819 in SLE, halts FT576 expansion
Cash, equivalents & investments: $391.1M as of March 31, 2024, including ~$80M offering and ~$20M private placement.
Fate Therapeutics treats first SLE patient with FT819; advances autoimmune pipeline
First SLE patient dosed in Phase 1 autoimmunity study of FT819 (CD19 CAR T); discharged after 3 days with no notable AEs.
Fate Therapeutics prices $100M equity offering and private placement
Underwritten offering of 14,545,454 shares at $5.50/share; net proceeds ~$74.7M.
Fate Therapeutics Q4 revenue $1.7M, cash $316M; FT522 first patient dosed, FT825 study initiated
Cash and investments $316.2M at Dec 31, 2023; Q4 GAAP operating expenses $49.8M (R&D $31.8M, G&A $17.9M).
Fate Therapeutics Q3 2023: $350M cash, multiple IND clearances, FT522 enrollment started
Cash, cash equivalents & investments $349.7M as of Sept 30, 2023; runway into 2H25.
Fate Therapeutics files $300M shelf, enters $100M ATM with Jefferies; terminates prior agreement
Filed S-3 shelf registration for up to $300M of common, preferred, debt, warrants, and units.
Fate Therapeutics loses summary judgment in patent case against Shoreline; plans appeal
Court granted Shoreline's summary judgment of non-infringement on Whitehead Patents covering iPSC technology.
Fate Therapeutics Q2 2023: cash $385M, FT522 Phase 1 start-up, FT825 IND planned 2H23
Cash position $385.2M as of June 30, 2023; runway into 2H25.
Fate Therapeutics announces FDA clearance of FT522 IND for Phase 1 trial in B-cell lymphoma
FDA allowed IND for FT522, an induced pluripotent stem cell-derived CAR NK-cell product candidate.
Fate Therapeutics Q1 revenue $59M via Janssen termination; cuts workforce, runway to 2H25
Q1 GAAP operating expenses $87.6M including $12.9M severance; revenue includes $52.3M from Janssen termination.
Fate Therapeutics reports Q4 revenue $44.4M; ends Janssen deal, cuts workforce to ~220
Cash and investments $441.2M plus $38.5M receivables; total ~$475M as of Dec 31, 2022.
Fate Therapeutics ends Janssen deal, cuts workforce to 220, discontinues four NK programs
Janssen collaboration terminated effective April 3, 2023; all activities wound down in Q1 2023.
Ono exercises option to Fate's HER2 CAR T-cell candidate; Fate to receive $12.5M
Ono exercised option to FT825/ONO-8250, triggering $12.5M option exercise fee to Fate.
Cash and investments $519.1M; Q3 revenue $15.0M from Janssen/ONO collaborations; R&D expense $79.8M.
Fate Therapeutics Q2 2022 revenue $18.5M; cash $580.8M; FT516 RMAT meeting set
Q2 2022 collaboration revenue $18.5M from Janssen and ONO; R&D expense $81.3M, G&A $20.4M; cash $580.8M at June 30.
Fate expands solid-tumor collaboration with Ono to include CAR NK cells, second target
Ono contributes novel binding domains for a second solid tumor antigen; partnership now includes CAR NK and CAR T-cell candidates.
Fate Therapeutics Q1 cash $641.7M, rev $18.4M; FT596+R-CHOP IND, FT536 solid tumor on track
Q1 2022 revenue of $18.4M from Janssen/Ono collaborations; R&D expense $72.1M, G&A $20.7M.
Fate Therapeutics Q4 2021 revenue $17.1M, cash $716.6M; FT596 data shows 69% ORR, FT516 gets RMAT
Q4 2021 revenue $17.1M from collaborations; R&D expenses $69.5M (incl. $9.4M stock comp).
FT516: 6 of 10 CAR T-naive patients in ongoing response at median 9.1 months; 3 of 8 prior CAR T patients achieve CR.
Fate Therapeutics Q3 cash $803.6M; FT596/FT516 show 71% and 73% ORR in lymphoma Ph1
Cash, equivalents and investments $803.6M at Sept 30, 2021; revenue $14.2M from collaborations.
Fate Therapeutics reports Q2 2021 results; first patient dosed with FT819 iPSC CAR T-cell therapy
Q2 2021 revenue $13.4M from collaborations; R&D expenses $48.0M; cash & investments $845.1M.
Concurrently with Mr. Abernethy’s election at the Annual Meeting, Timothy P. Coughlin’s term as a member of the Board and the Audit Committee thereof ended.
appointed Matthew Abernethy to the Board to serve as a Class III director
Bahram Valamehr, Ph.D., MBA has succeeded Mr. Wolchko in each of the Subsidiary Roles, effective as of January 1, 2025.
J. Scott Wolchko retired from his positions as President, Chief Executive Officer (“CEO”), Chief Financial Officer, Treasurer, principal executive officer, principal financial officer and principal accounting officer of the Company, effective as of December 31, 2024
On July 29, 2024, the Board, following a recommendation from the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), appointed Neelufar Mozaffarian, M.D., Ph.D., FACR, to the Board, to serve as a Class II director and member of the NCG Committee and the Science and Technology Committee of the Board.
On June 3, 2024, the board of directors (the “Board”) of Fate Therapeutics, Inc. (the “Company”) appointed J. Scott Wolchko, the Company’s President and Chief Executive Officer, to succeed Edward J. Dulac III as the Company’s Chief Financial Officer and also serve as the Company’s principal financial and accounting officer, effective immediately after Mr. Dulac’s resignation.
Mr. Dulac provided notice of his resignation from his position as the Company’s Chief Financial Officer on May 30, 2024, which resignation shall be effective as of June 14, 2024.
The Company’s board of directors intends to appoint J. Scott Wolchko, the Company’s President and Chief Executive Officer, to succeed Mr. Dulac as the Company’s Chief Financial Officer and also serve as the Company’s principal financial and accounting officer, effective immediately after Mr. Dulac’s resignation.
On May 30, 2024, Edward J. Dulac III provided notice of his resignation from his position as Chief Financial Officer of Fate Therapeutics, Inc. (the “Company”), which will be effective June 14, 2024.
Dr. Yu-Waye (Wayne) Chu, M.D. notified Fate Therapeutics, Inc. (the “Company”) that he intends to resign as Chief Medical Officer of the Company effective as of July 14, 2023 to pursue another opportunity.
the employment of Mark Plavsic, Ph.D., D.V.M., the Company’s Chief Technical Officer, is expected to terminate effective as of March 6, 2023.
On August 3, 2021, the Board appointed Yuan Xu, Ph.D. to the Board as a Class II director.
Max materiality 0.80 · Median 0.62 · Most common event other_material